Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)

This grant supports early-stage testing of pharmacologic or device-based interventions for mental disorders, using designs that assess both clinical effects and underlying mechanisms. It funds studies that evaluate dose-dependent neurophysiological, clinical, or behavioral outcomes linked to target modulation.